Pregabalin Capsule
Product Images NDC 60760-751

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

751-60 (Pregabalin 60760 751 60)

Pregabalin Capsules 75 mg label showing a quantity of 60 capsules. The label includes the NDC 60760-751-60 and indicates the capsules are manufactured by MSN Laboratories Private Limited, India, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. The label includes barcode, QR code, and standard storage instructions for controlled room temperature. Various lot and expiration information fields are shown with placeholders.*

FDA Label Image

Equation (Pregabain Gault Equation)

A formula calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and including an adjustment factor of 0.85 for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day compared to placebo. The graph illustrates that higher doses of Pregabalin correspond to greater percentages of patients experiencing pain improvement.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve chart showing the percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. Two lines compare Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line), illustrating patient response over varying levels of pain improvement.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin doses of 300 mg, 150 mg, and 75 mg taken two times a day, and placebo. The graph displays a descending trend in percent improved as percent pain improvement increases for all groups.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline, comparing three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The chart displays declining improvement percentages as pain improvement thresholds increase from greater than 0% to 100%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line chart showing the percent of patients improved by percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The chart illustrates the relationship between higher pain improvement percentages and the proportion of patients experiencing improvement for each group.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart showing responder rates (%) from two studies, Study E1 and Study E3. The chart compares placebo with various doses of Pregabalin given either BID (twice daily) or TID (three times daily). Study E1 includes placebo and doses from 50 mg to 600 mg per day, with responder rates ranging from 14% to 51%. Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID, with responder rates from 9% to 49%. Sample sizes (N) are shown below each group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A dose-response chart depicting seizure reduction as median percentage change from baseline on the vertical axis against dose in mg/day on the horizontal axis. It includes four datasets labeled Stukly E1BID, E2BID, E3BID, and E3TID, represented by different markers. The graph shows a positive correlation between dose and seizure reduction, with noted p-values indicating statistical significance.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A cumulative distribution plot showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis for different doses of Pregabalin (300 mg, 450 mg, 600 mg daily) and placebo. The plot displays four distinct lines representing each group.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve depicting the estimated percentage of subjects without LTR over a 180-day period. The graph compares two groups: Pregabalin (solid line) and Placebo (dashed line). The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis represents days from 0 to 180.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved on the vertical axis with percent improved from baseline to week 12 on the horizontal axis. Two lines represent Pregabalin and Placebo, showing higher improvement percentages for Pregabalin across the range. The graph is labeled with these treatments and statistical terms such as BOCF (Baseline Observation Carried Forward).*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A cumulative distribution plot showing the percent of subjects improved on the vertical axis versus the percent improved from baseline to week 16 on the horizontal axis. The graph compares Pregabalin (solid line) with Placebo (dotted line), illustrating greater improvement in subjects treated with Pregabalin compared to Placebo over the study period.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin, showing its molecular framework including carbon, hydrogen, nitrogen, and oxygen atoms arranged with an amino group, carboxyl group, and a branched aliphatic chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.